InvestorsObserver
×
News Home

Where Does CCXI Stock Rank in the Biotechnology Industry?

Friday, December 06, 2019 11:20 AM | InvestorsObserver Analysts

Mentioned in this article

Where Does CCXI Stock Rank in the Biotechnology Industry?

The 84 rating InvestorsObserver gives to ChemoCentryx Inc (CCXI) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 98 percent of stocks in the Biotechnology industry, CCXI’s 84 overall rating means the stock scores better than 84 percent of all stocks.

Click Here to get the full Stock Score Report on ChemoCentryx Inc (CCXI) Stock.

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 84 means the stock is more attractive than 84 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With ChemoCentryx Inc Stock Today?

ChemoCentryx Inc (CCXI) stock is down -3.45% while the S&P 500 has risen 0.95% as of 11:03 AM on Friday, Dec 6. CCXI is lower by -$1.07 from the previous closing price of $31.05 on volume of 140,366 shares. Over the past year the S&P 500 is higher by 16.73% while CCXI has risen 193.35%. CCXI lost -$0.92 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for ChemoCentryx Inc click here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App